Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease.

John B Kostis1

  • 1Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, Clinical Academic Building, Suite 5200, 125 Paterson Street, New Brunswick, NJ 08903-0019, USA. kostis@umdnj.edu

Cardiovascular Drugs and Therapy
|July 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors influencing the indication of coronary angiography in patients presenting with chest pain unspecified: an analysis of two decades (1994-2014).

International journal for quality in health care : journal of the International Society for Quality in Health Care·2024
Same author

US Initiative to Eliminate Racial and Ethnic Disparities in Health: The Impact on the Outcomes of ST-Segment-Elevation Myocardial Infarction in New Jersey.

Journal of the American Heart Association·2023
Same author

Epidemiology and trends in stroke mortality in the USA, 1975-2019.

International journal of epidemiology·2022
Same author

Change and the Perils of Induction.

International journal of cardiology. Cardiovascular risk and prevention·2022
Same author

Relation of Socioeconomic Status to 1-Year Readmission and Mortality in Patients With Acute Myocardial Infarction.

The American journal of cardiology·2022
Same author

Assessment of one-year risk of ischemic stroke versus major bleeding in patients with atrial fibrillation.

International journal of cardiology. Cardiovascular risk and prevention·2022

Managing hypertension and dyslipidemia is crucial for cardiovascular disease (CVD) prevention. Simultaneous treatment of multiple risk factors significantly reduces CVD events, improving patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Hypertension and dyslipidemia are key modifiable cardiovascular disease (CVD) risk factors.
  • Management strategies, pharmacologic agents, and targets have evolved significantly over 40 years.

Purpose of the Study:

  • To review the epidemiology of hypertension and hyperlipidemia.
  • To summarize evidence from clinical trials on pharmacologic therapy for reducing cardiovascular events.

Main Methods:

  • Review of epidemiological data on hypertension and hyperlipidemia.
  • Analysis of controlled clinical trials investigating pharmacologic interventions.

Main Results:

  • Co-occurrence of hypertension and dyslipidemia significantly increases CVD risk.

Related Experiment Videos

  • Clinical trials confirm benefits of treating hypertension and dyslipidemia, with early, intensive management yielding greatest benefits.
  • Simultaneous management of multiple risk factors can reduce CVD risk by over 50%, compared to ~30% for individual factors.

    • Conclusions:

    • Strong evidence supports the clinical benefits of treating hypertension and hypercholesterolemia.
    • Fixed-dose combination medications and integrated therapies improve risk factor management, adherence, and clinical outcomes.